Likewise, small-molecule BET inhibitors (JQ1 and I-BET) show anticancer effects in vitro and in vivo on acute myeloid leukemia (AML) [32,33], mixed lineage leukemia (MLL) [128], Burkitt’s lymphoma [33], medulloblastoma, which is the most common brain tumor in childhood [129], MYCN-amplified neuroblastoma [130], castration-resistant prostate cancer [131], Ewing’s sarcoma [132], and colorectal cancer [133]. This evidence concerns the gene KMT2A and acute myeloid leukemia.